Vera Therapeutics, Inc. $VERA Shares Purchased by BNP Paribas Financial Markets

BNP Paribas Financial Markets boosted its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA) by 86.9% in the fourth quarter, HoldingsChannel.com reports. The firm owned 474,668 shares of the company’s stock after acquiring an additional 220,692 shares during the period. BNP Paribas Financial Markets’ holdings in Vera Therapeutics were worth $24,037,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in VERA. GAMMA Investing LLC boosted its holdings in Vera Therapeutics by 50.5% in the fourth quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock worth $36,000 after purchasing an additional 236 shares during the period. Quantbot Technologies LP acquired a new position in Vera Therapeutics in the second quarter worth $51,000. Tower Research Capital LLC TRC boosted its holdings in Vera Therapeutics by 192.9% in the second quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company’s stock worth $99,000 after purchasing an additional 2,757 shares during the period. AlphaQuest LLC boosted its holdings in Vera Therapeutics by 414.2% in the third quarter. AlphaQuest LLC now owns 5,214 shares of the company’s stock worth $152,000 after purchasing an additional 4,200 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in Vera Therapeutics by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,106 shares of the company’s stock worth $157,000 after purchasing an additional 639 shares during the period. Institutional investors and hedge funds own 99.21% of the company’s stock.

Insider Buying and Selling at Vera Therapeutics

In related news, CEO Marshall Fordyce sold 18,500 shares of Vera Therapeutics stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $36.74, for a total transaction of $679,690.00. Following the sale, the chief executive officer directly owned 216,744 shares in the company, valued at $7,963,174.56. The trade was a 7.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 15.90% of the stock is currently owned by corporate insiders.

Vera Therapeutics Stock Performance

Shares of VERA opened at $32.29 on Friday. Vera Therapeutics, Inc. has a 1 year low of $19.07 and a 1 year high of $56.05. The company has a market cap of $2.32 billion, a price-to-earnings ratio of -5.83 and a beta of 0.93. The company has a debt-to-equity ratio of 0.15, a quick ratio of 13.64 and a current ratio of 13.64. The firm has a fifty day moving average of $37.71 and a 200-day moving average of $41.24.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.33) by ($0.36). During the same quarter in the prior year, the business earned ($0.81) EPS. As a group, equities analysts anticipate that Vera Therapeutics, Inc. will post -6.23 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Jefferies Financial Group reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Vera Therapeutics in a report on Tuesday. HC Wainwright lifted their price objective on shares of Vera Therapeutics from $90.00 to $110.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. TD Cowen reaffirmed a “buy” rating on shares of Vera Therapeutics in a report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vera Therapeutics in a research note on Monday, April 20th. Finally, Wolfe Research raised shares of Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 price target for the company in a report on Wednesday, March 11th. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Vera Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $78.00.

Vera Therapeutics Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.